About xtl biopharmaceuticals ltd - XTLB
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its product pipeline includes hCDR1 and rHuEPO. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.
XTLB At a Glance
XTL Biopharmaceuticals Ltd.
26 Ben-Gurion Street
Ramat Gan, Tel Aviv 5112001
| Phone | 972-3-611-6600 | Revenue | 0.00 | |
| Industry | Medical Specialties | Net Income | -765,021.13 | |
| Sector | Health Technology | Employees | 6 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
XTLB Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.651 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.05 |
XTLB Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -127,503.522 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
XTLB Liquidity
| Current Ratio | 0.395 |
| Quick Ratio | 0.395 |
| Cash Ratio | 0.181 |
XTLB Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -17.554 |
| Return on Equity | -29.532 |
| Return on Total Capital | -5,100.22 |
| Return on Invested Capital | -29.532 |
XTLB Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 1,793.333 |
| Total Debt to Total Assets | 162.048 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |